BR112019006565A2 - compostos de 1-fenilpropanona e seu uso - Google Patents
compostos de 1-fenilpropanona e seu usoInfo
- Publication number
- BR112019006565A2 BR112019006565A2 BR112019006565A BR112019006565A BR112019006565A2 BR 112019006565 A2 BR112019006565 A2 BR 112019006565A2 BR 112019006565 A BR112019006565 A BR 112019006565A BR 112019006565 A BR112019006565 A BR 112019006565A BR 112019006565 A2 BR112019006565 A2 BR 112019006565A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- phenylpropanone
- group
- relates
- substituent
- Prior art date
Links
- QCCDLTOVEPVEJK-UHFFFAOYSA-N phenylacetone Chemical class CC(=O)CC1=CC=CC=C1 QCCDLTOVEPVEJK-UHFFFAOYSA-N 0.000 title abstract 3
- -1 1-phenylpropanone compound Chemical class 0.000 abstract 3
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 abstract 1
- 206010029260 Neuroblastoma Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F11/00—Compounds containing elements of Groups 6 or 16 of the Periodic Table
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
a presente invenção refere-se a um composto de 1-fenilpropanona de fórmula (i), em que x é ch2 ou um átomo selecionado a partir do grupo que consiste em o, s e se, n é um número inteiro de 4 a 6, a é um substituinte selecionado a partir do grupo que consiste em 4-morfolila, 1-piperidinila, 4-metil-1-piperazinila, a sendo opcionalmente substituído com um substituinte de alquila de (c1-c3) ou acila de (c1-c3), com a condição que quando x for ch2, n é igual a 5, para uso como um agente antitumoral no tratamento de câncer de mama, leucemia linfática crônica ou neuroblastoma. a invenção também diz respeito aos novos compostos de 1-fenilpropanona e aos compostos como agentes antitumorais.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102016000098338A IT201600098338A1 (it) | 2016-09-30 | 2016-09-30 | Composti 1-fenilpropanone e loro impiego |
| PCT/IB2017/056010 WO2018060947A1 (en) | 2016-09-30 | 2017-09-29 | 1-phenylpropanone compounds and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019006565A2 true BR112019006565A2 (pt) | 2019-07-02 |
Family
ID=57960639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019006565A BR112019006565A2 (pt) | 2016-09-30 | 2017-09-29 | compostos de 1-fenilpropanona e seu uso |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11345673B2 (pt) |
| EP (1) | EP3518927B9 (pt) |
| JP (1) | JP7016370B2 (pt) |
| CN (1) | CN110035753B (pt) |
| AU (1) | AU2017335421A1 (pt) |
| BR (1) | BR112019006565A2 (pt) |
| CA (1) | CA3038008A1 (pt) |
| DK (1) | DK3518927T3 (pt) |
| ES (1) | ES2830749T3 (pt) |
| HR (1) | HRP20201769T1 (pt) |
| HU (1) | HUE052039T2 (pt) |
| IL (1) | IL265617B (pt) |
| IT (1) | IT201600098338A1 (pt) |
| LT (1) | LT3518927T (pt) |
| PT (1) | PT3518927T (pt) |
| RS (1) | RS61109B1 (pt) |
| RU (1) | RU2765102C2 (pt) |
| SI (1) | SI3518927T1 (pt) |
| WO (1) | WO2018060947A1 (pt) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54125630A (en) * | 1978-02-22 | 1979-09-29 | Nippon Zoki Pharmaceutical Co | Novel propanone derivative*its manufacture and medical composition containing it as active component |
| DE2842091A1 (de) * | 1978-09-27 | 1980-04-10 | Dow Chemical Co | Verfahren zur inaktivierung behuellter viren |
| JPS5549317A (en) * | 1978-10-02 | 1980-04-09 | Dow Chemical Co | Control of virus surrounded with phenylketones |
| US4931473A (en) * | 1989-02-15 | 1990-06-05 | Richardson-Vicks Inc. | Anesthetic oral compositions |
| WO2001028550A1 (en) | 1999-10-15 | 2001-04-26 | Mayo Foundation For Medical Education And Research | Topical anesthetics useful for treating cancer, autoimmune diseases and ischemia |
| WO2007143081A2 (en) * | 2006-06-02 | 2007-12-13 | The Ohio State University Research Foundation | Therapeutic agents for the treatment of lymphoid malignancies |
| FR2902789A1 (fr) | 2006-06-21 | 2007-12-28 | Genfit Sa | Derives de 1,3-diphenylpropane substitues, preparations et utilisations |
| AU2008307544A1 (en) * | 2007-10-02 | 2009-04-09 | University Of Rochester | Methods and compositions related to synergistic responses to oncogenic mutations |
| WO2012074960A2 (en) * | 2010-11-29 | 2012-06-07 | The Ohio State University Research Foundation | Fty720-derived anticancer agents |
-
2016
- 2016-09-30 IT IT102016000098338A patent/IT201600098338A1/it unknown
-
2017
- 2017-09-29 BR BR112019006565A patent/BR112019006565A2/pt active Search and Examination
- 2017-09-29 US US16/338,607 patent/US11345673B2/en active Active
- 2017-09-29 WO PCT/IB2017/056010 patent/WO2018060947A1/en unknown
- 2017-09-29 ES ES17791160T patent/ES2830749T3/es active Active
- 2017-09-29 SI SI201730491T patent/SI3518927T1/sl unknown
- 2017-09-29 AU AU2017335421A patent/AU2017335421A1/en not_active Abandoned
- 2017-09-29 RU RU2019113064A patent/RU2765102C2/ru active
- 2017-09-29 JP JP2019538741A patent/JP7016370B2/ja active Active
- 2017-09-29 EP EP17791160.9A patent/EP3518927B9/en active Active
- 2017-09-29 CN CN201780075159.1A patent/CN110035753B/zh active Active
- 2017-09-29 LT LTEP17791160.9T patent/LT3518927T/lt unknown
- 2017-09-29 RS RS20201322A patent/RS61109B1/sr unknown
- 2017-09-29 HU HUE17791160A patent/HUE052039T2/hu unknown
- 2017-09-29 CA CA3038008A patent/CA3038008A1/en active Pending
- 2017-09-29 PT PT177911609T patent/PT3518927T/pt unknown
- 2017-09-29 DK DK17791160.9T patent/DK3518927T3/da active
-
2019
- 2019-03-26 IL IL265617A patent/IL265617B/en unknown
-
2020
- 2020-11-02 HR HRP20201769TT patent/HRP20201769T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3518927A1 (en) | 2019-08-07 |
| IT201600098338A1 (it) | 2018-03-30 |
| IL265617B (en) | 2022-01-01 |
| JP7016370B2 (ja) | 2022-02-21 |
| RS61109B1 (sr) | 2020-12-31 |
| CN110035753B (zh) | 2022-08-05 |
| RU2019113064A3 (pt) | 2020-10-30 |
| EP3518927B1 (en) | 2020-08-12 |
| US11345673B2 (en) | 2022-05-31 |
| SI3518927T1 (sl) | 2021-01-29 |
| HUE052039T2 (hu) | 2021-04-28 |
| ES2830749T3 (es) | 2021-06-04 |
| RU2765102C2 (ru) | 2022-01-25 |
| JP2019529576A (ja) | 2019-10-17 |
| WO2018060947A1 (en) | 2018-04-05 |
| CA3038008A1 (en) | 2018-04-05 |
| AU2017335421A1 (en) | 2019-05-16 |
| US20200039946A1 (en) | 2020-02-06 |
| DK3518927T3 (da) | 2020-11-09 |
| EP3518927B9 (en) | 2021-04-07 |
| RU2019113064A (ru) | 2020-10-30 |
| LT3518927T (lt) | 2021-01-25 |
| IL265617A (en) | 2019-05-30 |
| HRP20201769T1 (hr) | 2021-03-19 |
| CN110035753A (zh) | 2019-07-19 |
| PT3518927T (pt) | 2020-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR123996A2 (es) | Compuestos tricíclicos novedosos como agentes antineoplásicos | |
| PH12017502334A1 (en) | Polycyclic amide derivative as cdk9 inhibitors | |
| CR20180367A (es) | Compuestos útiles como inhibidores de cinasa | |
| PE20160995A1 (es) | Inhibidores de syk | |
| PH12018502535A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| AR108012A1 (es) | Derivados de azaespiro[3,4]octan-6-ona como inhibidores de magl | |
| BR112019000696A2 (pt) | antagonistas de tlr7/8 e uso dos mesmos | |
| PH12018502497A1 (en) | Adenosine derivatives for use in the treatment of cancer | |
| CU20160120A7 (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| DOP2015000289A (es) | Compuestos de 3,4-dihidroisoquinolin-2(1h)-ilo | |
| PH12019501178A1 (en) | Thiopene derivatives as antiviral agents | |
| MX2021006404A (es) | Derivados de piridona policiclica sustituida y profarmaco de los mismos. | |
| CR20150268A (es) | Compuestos novedosos | |
| MA38982A1 (fr) | Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl | |
| BR112016026046A8 (pt) | uso de compostos de tienotriazolodiazepina | |
| MX2018016290A (es) | Agente antidesgaste. | |
| CR20160198A (es) | Derivados de etinilo-imidazolidín-2, 4-diona como moduladore mglur4 | |
| CO2019001871A2 (es) | Derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunes o inflamatorias o cánceres. | |
| MX2018001576A (es) | Piridinas y su uso en el tratamiento del cancer. | |
| CR20160070A (es) | Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos | |
| MX2019009356A (es) | Sulfinilpiridinas y su uso en el tratamiento del cancer. | |
| MX2015013531A (es) | Alquil glicosidos como surfactantes. | |
| MX2016014240A (es) | Composicion limpiadora. | |
| MX2020004517A (es) | Composiciones que comprenden un polímero acrílico y procesos para prepararlas. | |
| BR112019003130A2 (pt) | agonista de ppargama para tratamento de cânceres de sangue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] |